Heart 1999;82:570-574 ( November )

Use of antithrombotic measures for stroke prevention in atrial fibrillation

I Perez^a, A Melbourn^a, L Kalra^b

^a Orpington Stroke Unit, Bromley Hospitals NHS Trust, Kent, UK, ^b Department of Medicine, Guy's, King's and Thomas' School of Medicine, Denmark Hill Campus, Bessemer Road, London SE5 9PJ, UK

Correspondence to: Professor Kalra email: lalit.kalra{at}kcl.ac.uk

Accepted for publication 2 August 1999

OBJECTIVETo evaluate appropriateness of antithrombotic use to prevent stroke in atrial fibrillation.
DESIGN, PATIENTS344 patients with atrial fibrillation, stratified by age, were assessed clinically for contraindications to anticoagulation and stroke risk. The use of warfarin and aspirin was compared with recommendations for anticoagulation derived from pooled clinical trial data.
RESULTSLow risk of stroke was seen in 47 (14%) patients, moderate risk in 213 (62%), and high risk in 84 (24%) patients included in the sample (mean (SD) age 68.4 (17.2) years, 42% men). The proportion of patients requiring anticoagulation varied from 258/344 (75%) to 72/344 (21%) depending upon criteria used, of whom 86/258 (33%) and 36/72 (50%) were receiving warfarin, respectively. Warfarin or aspirin were not being used in 124/297 (42%) patients with moderate to high risk, whereas anticoagulation was being undertaken in 13/47 (27%) patients at low risk of stroke. Antithrombotic use (warfarin or aspirin) was significantly less common in patients over 75 years of age, regardless of absence of contraindications and eligibility according to various criteria (p < 0.001).
CONCLUSIONSA clear need for anticoagulation using clinical criteria existed in about 25% of patients in atrial fibrillation presenting to medical clinics who were at high risk of stroke. Of these, only 50% of eligible patients were being anticoagulated. Appropriate anticoagulation needs to be based on risk assessment rather than age. Consensus is therefore needed on appropriate antithrombotic use in clinical practice.


Keywords: stroke prevention; atrial fibrillation; warfarin; aspirin; antithrombotics

---

© 1999 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kalra, L, Lip, G Y H, on behalf of the Guideline Development Group for t, (2007). Antithrombotic treatment in atrial fibrillation. Heart 93: 39-44 [Full Text]  
• Capucci, A., Santini, M., Padeletti, L., Gulizia, M., Botto, G., Boriani, G., Ricci, R., Favale, S., Zolezzi, F., Di Belardino, N., Molon, G., Drago, F., Villani, G. Q., Mazzini, E., Vimercati, M., Grammatico, A., on behalf of the Italian AT500 Registry Investigat, (2005). Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. J Am Coll Cardiol 46: 1913-1920 [Abstract] [Full Text]  
• Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J.-Y., Prins, M. H., Levy, S., Crijns, H. J.G.M., on behalf of the Euro Heart Survey Investigators, (2005). Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26: 2422-2434 [Abstract] [Full Text]  
• O'Donnell, M., Agnelli, G., Weitz, J. I. (2005). Emerging therapies for stroke prevention in atrial fibrillation. Eur Heart J Suppl 7: C19-C27 [Abstract] [Full Text]  
• Bellelli, G., Guerini, F., Bianchetti, A., Trabucchi, M., Evans, A., Kalra, L. (2002). Anticoagulation Treatment in Disabled Patients. Arch Intern Med 162: 107-108 [Full Text]  
• Wehinger, C., Stollberger, C., Langer, T., Schneider, B., Finsterer, J. (2001). Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation. Stroke 32: 2246-2252 [Abstract] [Full Text]  
• Quilliam, B. J., Lapane, K. L., Leibson, C. (2001). Clinical Correlates and Drug Treatment of Residents With Stroke in Long-Term Care Editorial Comment. Stroke 32: 1385-1393 [Abstract] [Full Text]  
• Humphries, K. H., Kerr, C. R., Connolly, S. J., Klein, G., Boone, J. A., Green, M., Sheldon, R., Talajic, M., Dorian, P., Newman, D. (2001). New-Onset Atrial Fibrillation : Sex Differences in Presentation, Treatment, and Outcome. Circulation 103: 2365-2370 [Abstract] [Full Text]  
• Chugh, S. S., Blackshear, J. L., Shen, W.-K., Hammill, S. C., Gersh, B. J. (2001). Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37: 371-378 [Abstract] [Full Text]  
• Hart, R. G. (2000). Anticoagulation therapy for patients with atrial fibrillation. CMAJ 163: 956-957 [Full Text]  
• Ellis, S. J, Hans, R., Mant, J., Fitzmaurice, D., Murray, E., Hobbs, R., Evans, A., Perez, I., Kalra, L., Rutten, F. H, Hak, E., Hoes, A. W, Rose, P E, Taylor, F. C., Ebrahim, S., Hellemons, B., Langenberg, M., van Ree, J., Knottnerus, A., Lodder, J., Vermeer, F., Schouten, H. (2000). Using anticoagulation or aspirin to prevent stroke. BMJ 320: 1008-1008 [Full Text]  
• HART, R. G (1999). Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 82: 539-540 [Full Text]